This phase I/II study is seeking to determine the appropriate dose level of Radium-223 when given in addition to combination therapy (177Lu-PSMA-I&T) in people with metastatic, castration-resistant prostate cancer.
This trial is treating patients with metastatic castration-resistant prostate cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
Summary
This study has two stages: dose escalation and dose expansion. In the dose escalation stage, eligible participants will receive 7.4 GBq of 177Lu-PSMA-I&T on Day 1 of every 6 week Cycle. Radium-223 will be administered concurrently every 6 weeks. The dose of Radium-223 will vary in dose-escalation, between 27.5 kBq/kg and 55 kBq/kg. Up to 6 Cycles will be given.
The maximum tolerated dose of Radium-223 will be used during the second stage, dose expansion.
Recruiting Hospitals Read More